What Deciduous Therapeutics does

Deciduous Therapeutics is an early-stage, venture-backed biotechnology company headquartered at 953 Indiana Street in San Francisco, California. The company is developing a novel class of immune modulatory therapies that activate invariant natural killer T (iNKT) cells — via lipid antigen presentation — to selectively eliminate senescent cells, which accumulate with age and drive inflammation, extracellular matrix remodeling, and progression of age-related diseases. The foundational scientific discovery was published in the peer-reviewed journal Med (Cell Press) in 2021, and the company has demonstrated in vivo proof-of-concept in both fibrotic and metabolic disease models, achieving therapeutically relevant endpoints and durable effects in preclinical studies. Initial pipeline focus is on age-related fibrotic and metabolic diseases, with explicit plans to expand into additional indications through multiple activation approaches.

The company is led by Co-founder and CEO Robin Mansukhani (formerly co-founder and President & CEO of Alzeca Biosciences) and Scientific Founder Dr. Anil Bhushan, with VP of Research Dr. Vladi Juric (postdoctoral training under Nobel Laureate J. Michael Bishop, ex-Gilead, ex-Pionyr Immunotherapeutics) overseeing R&D. The team includes roughly 11–50 employees spanning clinical development, toxicology, medicinal chemistry, and immunology, supported by a Scientific Advisory Board that includes Dr. Max Krummel and Dr. Eric Verdin, an independent board member Robert Forrester, and high-profile investor Thomas Ebeling (former CEO of Novartis). The company has secured two incubator Golden Ticket awards (Bakar Labs at UC Berkeley in October 2021 and Eisai Innovation/MBC BioLabs in November 2021), along with approximately $16.5 million in disclosed venture funding from investors including CRV, 8VC, Presight Capital, The Longevity Fund, Global Brain Corporation, Bold Capital Partners, Healthspan Capital, Humboldt Fund, and Owl Capital.

Deciduous Therapeutics is pre-revenue and does not yet have commercial products or established pricing. The business model is structured around traditional pharmaceutical development: venture-backed R&D funding flows into preclinical research, with anticipated future revenue from pharmaceutical product sales and/or licensing upon successful clinical development and regulatory approval. Marketing and GTM efforts to date have been concentrated on top-of-funnel scientific outreach, including peer-reviewed publication in Med, conference presentations (Longevity Leaders World Congress), earned media in outlets such as STAT News and Endpoints News, podcast appearances, and partnerships with advocacy organizations such as the Alliance for Longevity Initiatives. The eventual commercial GTM motion is expected to follow enterprise field sales patterns through traditional pharmaceutical distribution channels, contingent on successful clinical translation.

Name

Deciduous Therapeutics

Legal name

Deciduous Therapeutics Inc.

Website

https://deciduoustx.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Deciduous Therapeutics is a venture-backed, pre-revenue biotech developing immunotherapies that activate invariant natural killer T (iNKT) cells to selectively eliminate senescent cells, targeting age-related fibrotic and metabolic diseases.

Ownership category

akta.pro rank

Product category

Senolytic Immunotherapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

akta.pro secondary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

Keywords

• Senolytic immunotherapy
• Cellular senescence drugs
• Age-related disease therapeutics
• INKT cell activation
• Fibrotic disease treatment

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Novel Medicines Development: Pre-revenue biotech company developing novel immunotherapies for age-related diseases. Revenue will be generated through pharmaceutical product sales upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Deciduous Therapeutics is a pre-revenue biotech developing a novel class of immune modulatory therapies that activate invariant natural killer T (iNKT) cells to selectively eliminate senescent cells. The company's pipeline targets multiple age-related diseases including fibrotic and metabolic conditions, leveraging lipid antigen presentation as an endogenous immune surveillance mechanism for senolytic therapy.

Product overview

Deciduous Therapeutics is developing novel immunotherapies that activate endogenous immune mechanisms to selectively eliminate senescent cells. Their therapeutic approach focuses on activating invariant natural killer T (iNKT) cells to clear pathogenic senescent cells, offering a differentiated mechanism compared to traditional senolytic drugs. The company's pipeline targets multiple age-related diseases including fibrotic and metabolic diseases. As an early-stage biotech company, they are translating discoveries from their scientific founder's lab toward clinical applications.

Differentiator

Problem solved

Functional benefit

Products and services

• NKT Cell-Activating Senolytic Immunotherapy Pipeline

Quantifiable outcome

• Demonstrated senescent cell clearance in disease models through NKT cell activation
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core and minor.

• MBC BioLabs / Eisai InnovationcoreStrategic or Co-development Partner · 1 November 2021Deciduous Therapeutics won the inaugural Eisai Innovation, Inc. and MBC BioLabs Golden Ticket Competition in 2021. The competition provides winning companies with lab space in MBC BioLabs facility in San Francisco to pursue drug discovery and innovation for potential future benefit of patients. MBC BioLabs provides state-of-the-art laboratory facilities and an ecosystem supporting biotech startups.
• Bakar LabscoreStrategic or Co-development Partner · 21 October 2021Deciduous Therapeutics won a 2021 Golden Ticket from Bakar Labs, the flagship life science incubator at UC Berkeley's Bakar BioEnginuity Hub. The Golden Ticket grants access to free lab space and facilities for one year, providing a substantial head start in commercializing technologies. Bakar Labs offers more than 20,000 square feet of premium experimental space and access to campus resources, industry partners, and a community of up to 50 fellow resident startups. The program is sponsored by AbbVie as an inaugural member of Bakar Labs Incubator.
• Alliance for Longevity Initiatives (A4LI)minorGTM or Marketing PartnerDeciduous Therapeutics CEO Robin Mansukhani participated in the A4LI virtual conference on longevity science, joining other longevity scientists, biotech executives, and investors to discuss advances in aging biology, therapeutic development, and healthspan extension.

Scale indicators2 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• MiNK Therapeutics: Clinical-stage immuno-oncology company developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases. Most direct peer given the shared iNKT-cell therapeutic axis; Deciduous even has team alumni (Darrian Moskowitz) from MiNK's allogeneic iNKT program.
• Unity Biotechnology: Clinical-stage senolytic drug developer (UBX0101, UBX1325) targeting senescent cells for age-related ophthalmologic and musculoskeletal diseases. Direct therapeutic-target peer for senescent-cell clearance in age-related disease, although via small-molecule rather than immune-mediated mechanism.
• Oisín Biotechnologies: Privately held senolytic company developing plasmid-DNA-based gene therapy to selectively eliminate senescent cells. Pursues the same senescent-cell-clearance therapeutic hypothesis as Deciduous but via a fundamentally different (gene-therapy) modality.
• Cleara Biotech: Early-stage senolytic startup developing small-molecule FOXO4-DRI peptide therapeutics to selectively clear senescent cells. Direct therapeutic-target competitor in the same senolytic space as Deciduous.

Emerging players

• Pliant Therapeutics: Clinical-stage biotech developing integrin-targeting therapies for fibrotic diseases including idiopathic pulmonary fibrosis (IPF). Overlaps with Deciduous's initial fibrotic-disease indication focus and shares Dr. Greg Cosgrove (former VP Clinical Development at Pliant) on the team.
• BioAge Labs: Clinical-stage aging therapeutics company developing small-molecule drugs that target pathways driving age-related disease. Comparable aging-therapeutics stage and target patient population, and Deciduous CEO appeared on BioAge's 'Translating Aging' podcast — direct ecosystem overlap.
• Pionyr Immunotherapeutics: Immuno-oncology company developing myeloid-targeting antibodies (acquired by Gilead in 2023). Strong ecosystem overlap: Deciduous VP Research Dr. Vladi Juric previously led myeloid-reprogramming antibody programs at Pionyr toward the clinic.

Broad incumbents

• Altos Labs: Well-capitalized ($3B+ raised) cell-reprogramming and aging-biology company pursuing cellular rejuvenation therapies. Operates in the same longevity/age-related-disease thesis at vastly greater scale and capital depth; represents the bull-case ceiling for the aging-therapeutics market.
• Calico Labs: Alphabet-backed longevity R&D organization pursuing fundamental research into the biology of aging and age-related disease. Larger, broader portfolio player in the same aging-therapeutics thesis with deep pharma-style resources.
• Insilico Medicine: AI-driven drug-discovery company advancing aging and age-related-disease programs (including IPF and T2D candidates) into the clinic. Operates in the same age-related-disease pipeline space with significantly larger resources and broader pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/deciduous-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deciduous Therapeutics